U.S. Leads Global Multiple Sclerosis Market Driven by Early Detection and High-Efficacy Therapies
The U.S. is a primary contributor to the global multiple sclerosis (MS) market, which is experiencing significant growth due to a clinical preference for early initiation of high-efficacy disease-modifying therapies. Neurologists are increasingly adopting aggressive early intervention strategies over traditional escalation approaches to manage newly diagnosed MS patients. This shift is supported by growing clinical evidence, highlighted by organizations like the National Multiple Sclerosis Society, which indicates that early high-efficacy treatment can reduce long-term disability accumulation and relapse frequency. The U.S. market benefits from substantial healthcare expenditure, advanced diagnostic technologies, robust clinical research capabilities, and significant pharmaceutical investments. Advanced MRI-based diagnostic criteria, endorsed by the Multiple Sclerosis International Federation (MSIF), along with expanding access to oral and monoclonal antibody therapies, are facilitating earlier diagnoses a... 
